A judge said Friday that he planned to approve a deal for OxyContin maker Purdue Pharma and members of the Sackler family who ...

NEW DELHI : The Centre has extended the deadline for applying for the ₹ 5,000-crore Promotion of Research and Innovation in ...

In our news wrap Friday, a federal bankruptcy judge will approve Purdue Pharma’s latest deal to settle lawsuits over the ...

Fintel reports that on November 13, 2025, D. Boral Capital maintained coverage of Medicus Pharma (NasdaqCM:MDCX) with a Buy recommendation. Analyst Price Forecast Suggests 916.96% Upside As of ...

Strategic process -- Formal engagement with Evercore concluded; current focus is on Phase III clinical execution, with ...

Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH ...

OxyContin maker Purdue Pharma, blamed for helping to fuel a deadly opioid crisis, said Friday that a US bankruptcy judge will ...

While AI has accelerated drug discovery, the same technology can address clinical trial bottlenecks that have persisted for ...

New regulatory initiatives in 2026 impacted DE&I, creating challenges and opportunities for the pharmaceutical industry. Companies are urged to integrate DE&I into core operations, focusing on patient ...

The tech used my right arm hanging down at my side, asking questions the whole time. In addition, the cuff was on my arm ...

Praveen Rao Akkinepally, Country President and Managing Director, AstraZeneca Pharma India, on new launches, India’s ...

If you want to venture beyond what we call the CPG, consumer packaged goods, world, I think you’d do very well with owning J&J or Amgen… J&J’s getting out of everything non-proprietary, ...